Back to Journals » Clinical Ophthalmology » Volume 13

Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis

Authors Sheha H, Tighe S, Hashem O, Hayashida Y

Received 21 May 2019

Accepted for publication 25 September 2019

Published 7 October 2019 Volume 2019:13 Pages 1973—1980

DOI https://doi.org/10.2147/OPTH.S185184

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Nicola Ludin

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Hosam Sheha,1–3 Sean Tighe,2 Omar Hashem,3 Yasutaka Hayashida4

1Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, Northwell Health, New York, NY, USA; 2Department of Ophthalmology, Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA; 3Department of Ophthalmology, Research Institute of Ophthalmology, Cairo, Egypt; 4Department of Ophthalmology, Osaka University Graduate School of Medicine, Suita, Japan

Correspondence: Hosam Sheha
Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, 210 E 64th Street, New York, NY 10065, USA
Tel +1 305-710-4709
Email hoss88@gmail.com

Abstract: Neurotrophic keratitis is an underdiagnosed degenerative condition induced by impairment to the corneal nerves which may lead to persistent epithelial defects and corneal blindness. Current medical and surgical treatments are only supportive and poorly tackle the underlying problem of corneal anesthesia; hence, fail to provide a permanent cure. Cenegermin is a newly introduced recombinant human nerve growth factor (rhNGF) that may address this issue. Preliminary clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis; however, the clinical experience with this drug is still limited. This review summarizes the pathogenesis and management of neurotrophic keratitis as well as the mechanism of action, uses, and limitations of cenegermin eye drops in the treatment of neurotrophic keratitis.

Keywords: cenegermin, corneal nerves, neurotrophic keratitis, nerve growth factors, persistent epithelial defect


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]